Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

The South African universal preschool year: a case study of policy development and implementation.

Richter L, Samuels ML.

Child Care Health Dev. 2018 Jan;44(1):12-18. doi: 10.1111/cch.12511. Review.

PMID:
29235166
2.

Epigenomic Deconvolution of Breast Tumors Reveals Metabolic Coupling between Constituent Cell Types.

Onuchic V, Hartmaier RJ, Boone DN, Samuels ML, Patel RY, White WM, Garovic VD, Oesterreich S, Roth ME, Lee AV, Milosavljevic A.

Cell Rep. 2016 Nov 15;17(8):2075-2086. doi: 10.1016/j.celrep.2016.10.057.

3.

Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation.

Abdel-Mohsen M, Chavez L, Tandon R, Chew GM, Deng X, Danesh A, Keating S, Lanteri M, Samuels ML, Hoh R, Sacha JB, Norris PJ, Niki T, Shikuma CM, Hirashima M, Deeks SG, Ndhlovu LC, Pillai SK.

PLoS Pathog. 2016 Jun 2;12(6):e1005677. doi: 10.1371/journal.ppat.1005677. eCollection 2016 Jun.

4.

Correction: Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab RB, Peterson MR, Lowy AM, Frazer KA, Harismendy O.

Genome Med. 2014 Jul 26;6(7):53. doi: 10.1186/s13073-014-0053-y. eCollection 2014. No abstract available.

5.

Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.

Alakus H, Babicky ML, Ghosh P, Yost S, Jepsen K, Dai Y, Arias A, Samuels ML, Mose ES, Schwab RB, Peterson MR, Lowy AM, Frazer KA, Harismendy O.

Genome Med. 2014 May 29;6(5):43. doi: 10.1186/gm559. eCollection 2014.

6.

Emerging technologies in extracellular vesicle-based molecular diagnostics.

Jia S, Zocco D, Samuels ML, Chou MF, Chammas R, Skog J, Zarovni N, Momen-Heravi F, Kuo WP.

Expert Rev Mol Diagn. 2014 Apr;14(3):307-21. doi: 10.1586/14737159.2014.893828. Epub 2014 Feb 27. Review.

PMID:
24575799
7.

Detection of cancer DNA in plasma of patients with early-stage breast cancer.

Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg D, Kessler J, Jeter S, Samuels ML, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC, Park BH.

Clin Cancer Res. 2014 May 15;20(10):2643-2650. doi: 10.1158/1078-0432.CCR-13-2933. Epub 2014 Feb 6.

8.

BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles.

Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, Loguidice L, Soto H, Garrett M, Zhu LD, Sivaraman S, Chen C, Wong ET, Carter BS, Hochberg FH, Breakefield XO, Skog J.

Mol Ther Nucleic Acids. 2013 Jul 23;2:e109. doi: 10.1038/mtna.2013.28.

9.

High-resolution dose-response screening using droplet-based microfluidics.

Miller OJ, El Harrak A, Mangeat T, Baret JC, Frenz L, El Debs B, Mayot E, Samuels ML, Rooney EK, Dieu P, Galvan M, Link DR, Griffiths AD.

Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):378-83. doi: 10.1073/pnas.1113324109. Epub 2011 Dec 27.

10.

Application of microdroplet PCR for large-scale targeted bisulfite sequencing.

Komori HK, LaMere SA, Torkamani A, Hart GT, Kotsopoulos S, Warner J, Samuels ML, Olson J, Head SR, Ordoukhanian P, Lee PL, Link DR, Salomon DR.

Genome Res. 2011 Oct;21(10):1738-45. doi: 10.1101/gr.116863.110. Epub 2011 Jul 14.

11.

Microdroplet-based PCR enrichment for large-scale targeted sequencing.

Tewhey R, Warner JB, Nakano M, Libby B, Medkova M, David PH, Kotsopoulos SK, Samuels ML, Hutchison JB, Larson JW, Topol EJ, Weiner MP, Harismendy O, Olson J, Link DR, Frazer KA.

Nat Biotechnol. 2009 Nov;27(11):1025-31. doi: 10.1038/nbt.1583. Epub 2009 Nov 1. Erratum in: Nat Biotechnol. 2010 Feb;28(2):178.

12.

Droplet microfluidic technology for single-cell high-throughput screening.

Brouzes E, Medkova M, Savenelli N, Marran D, Twardowski M, Hutchison JB, Rothberg JM, Link DR, Perrimon N, Samuels ML.

Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14195-200. doi: 10.1073/pnas.0903542106. Epub 2009 Jul 15.

13.

Fluorescence-activated droplet sorting (FADS): efficient microfluidic cell sorting based on enzymatic activity.

Baret JC, Miller OJ, Taly V, Ryckelynck M, El-Harrak A, Frenz L, Rick C, Samuels ML, Hutchison JB, Agresti JJ, Link DR, Weitz DA, Griffiths AD.

Lab Chip. 2009 Jul 7;9(13):1850-8. doi: 10.1039/b902504a. Epub 2009 Apr 23.

PMID:
19532959
14.

Detection and analysis of low-abundance cell-surface biomarkers using enzymatic amplification in microfluidic droplets.

Joensson HN, Samuels ML, Brouzes ER, Medkova M, Uhlén M, Link DR, Andersson-Svahn H.

Angew Chem Int Ed Engl. 2009;48(14):2518-21. doi: 10.1002/anie.200804326.

PMID:
19235824
15.

Functional protein arrays to facilitate drug discovery and development.

Michaud GA, Samuels ML, Schweitzer B.

IDrugs. 2006 Apr;9(4):266-72.

PMID:
16596480
16.

Global role for chromatin remodeling enzymes in mitotic gene expression.

Krebs JE, Fry CJ, Samuels ML, Peterson CL.

Cell. 2000 Sep 1;102(5):587-98.

17.

Functional interaction between GCN5 and polyamines: a new role for core histone acetylation.

Pollard KJ, Samuels ML, Crowley KA, Hansen JC, Peterson CL.

EMBO J. 1999 Oct 15;18(20):5622-33.

18.
19.

Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes.

McCarthy SA, Samuels ML, Pritchard CA, Abraham JA, McMahon M.

Genes Dev. 1995 Aug 15;9(16):1953-64.

21.

Evaluation of an orally administered vaccine, using hydrogels containing bacterial exotoxins of Pasteurella haemolytica, in cattle.

Bowersock TL, Shalaby WS, Levy M, Samuels ML, Lallone R, White MR, Borie DL, Lehmeyer J, Park K.

Am J Vet Res. 1994 Apr;55(4):502-9.

PMID:
8017696
22.

Proto-oncogenes and plasticity in cell signaling.

Bishop JM, Capobianco AJ, Doyle HJ, Finney RE, McMahon M, Robbins SM, Samuels ML, Vetter M.

Cold Spring Harb Symp Quant Biol. 1994;59:165-71. Review. No abstract available.

PMID:
7587066
24.

Self-reported sexual behaviors of schizophrenic clients and noninstitutionalized adults.

Bell CE, Wringer PH, Davidhizar R, Samuels ML.

Perspect Psychiatr Care. 1993 Apr-Jun;29(2):30-6. Review.

PMID:
8516095
25.

Effect of the somatostatin analogue octreotide on gastric fluid pH in ponies.

Sojka JE, Weiss JS, Samuels ML, You GM.

Am J Vet Res. 1992 Oct;53(10):1818-21.

PMID:
1456527
26.

Pulmonary immunity in calves following stimulation of the gut-associated lymphatic tissue by bacterial exotoxin.

Bowersock TL, Walker RD, Samuels ML, Moore RN.

Can J Vet Res. 1992 Apr;56(2):142-7.

27.

Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs.

Scott-Moncrieff JC, Chan TC, Samuels ML, Cook JR, Coppoc GL, DeNicola DB, Richardson RC.

Cancer Chemother Pharmacol. 1991;29(1):13-8.

PMID:
1742843
28.

The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients.

Chong CD, Logothetis CJ, Savaraj N, Fritsche HA, Gietner AM, Samuels ML.

J Clin Pharmacol. 1988 Aug;28(8):714-8.

PMID:
3216038
29.

Successful treatment of pure endodermal sinus tumors in adult men.

Chong CD, Logothetis CJ, von Eschenbach AC, Ayala AG, Samuels ML.

J Clin Oncol. 1988 Feb;6(2):303-7.

PMID:
2448426
30.

Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patients.

Logothetis CJ, Samuels ML, Ogden SL, Dexeus FH, Chong CD.

J Urol. 1987 Oct;138(4):789-94.

PMID:
3656535
31.

Sarcomatoid renal cell carcinoma. A treatable entity.

Sella A, Logothetis CJ, Ro JY, Swanson DA, Samuels ML.

Cancer. 1987 Sep 15;60(6):1313-8.

PMID:
2441841
32.

Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients.

Logothetis CJ, Swanson DA, Dexeus F, Chong C, Ogden S, Ayala AG, von Eschenbach AC, Johnson DE, Samuels ML.

J Clin Oncol. 1987 Jun;5(6):906-11.

PMID:
2438389
33.

Sarcomatoid renal cell carcinoma: clinicopathologic. A study of 42 cases.

Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA.

Cancer. 1987 Feb 1;59(3):516-26.

PMID:
3791160
34.

Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimens.

Dexeus FH, Logothetis CJ, Samuels ML, Ayala AG, Hossan E.

J Urol. 1987 Jan;137(1):122-5.

PMID:
3795354
35.

Use of analysis of covariance in clinical trials: a clarification.

Samuels ML.

Control Clin Trials. 1986 Dec;7(4):325-9.

PMID:
3802852
36.

Phase II study of spirogermanium in metastatic prostate cancer.

Dexeus FH, Logothetis C, Samuels ML, Hossan B.

Cancer Treat Rep. 1986 Sep;70(9):1129-30. No abstract available.

PMID:
3742495
37.

Prognostic factors in disseminated germ cell tumors.

Logothetis CJ, Samuels ML.

J Clin Oncol. 1986 Aug;4(8):1278-80. No abstract available.

PMID:
3016207
38.

Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients.

Logothetis CJ, Samuels ML, Selig DE, Ogden S, Dexeus F, Swanson D, Johnson D, von Eschenbach A.

Am J Med. 1986 Aug;81(2):219-28.

PMID:
2426944
39.

Carcinoembryonic antigen and beta-human chorionic gonadotropin as serum markers for advanced urothelial malignancies.

Dexeus F, Logothetis C, Hossan E, Samuels ML.

J Urol. 1986 Aug;136(2):403-7.

PMID:
2426474
40.

Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report.

Logothetis CJ, Samuels ML, Selig DE, Johnson DE, Swanson DA, von Eschenbach AC.

J Urol. 1985 Dec;134(6):1127-30.

PMID:
2414470
41.
42.

Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases.

Logothetis CJ, Samuels ML, Ogden S, Dexeus FH, Swanson D, Johnson DE, von Eschenbach A.

J Urol. 1985 Sep;134(3):460-4.

PMID:
2993671
43.

Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer.

Dexeus F, Logothetis CJ, Samuels ML, Hossan E, von Eschenbach AC.

Cancer Treat Rep. 1985 Jul-Aug;69(7-8):885-6.

PMID:
4016795
44.

Testicular cancer in homosexual men with cellular immune deficiency: report of 2 cases.

Logothetis CJ, Newell GR, Samuels ML.

J Urol. 1985 Mar;133(3):484-6.

PMID:
2579253
45.

Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis.

Logothetis CJ, Samuels ML, Selig D, Swanson D, Johnson DE, von Eschenbach AC.

J Clin Oncol. 1985 Mar;3(3):326-35.

PMID:
2579213
46.

Chemotherapy of extragonadal germ cell tumors.

Logothetis CJ, Samuels ML, Selig DE, Dexeus FH, Johnson DE, Swanson DA, von Eschenbach AC.

J Clin Oncol. 1985 Mar;3(3):316-25.

PMID:
2579212
47.
48.
49.

The prognostic significance of endodermal sinus tumor histology among patients treated for stage III nonseminomatous germ cell tumors of the testes.

Logothetis CJ, Samuels ML, Trindade A, Grant C, Gomez L, Ayala A.

Cancer. 1984 Jan 1;53(1):122-8.

PMID:
6317156
50.

Superior vena cava obstruction in small cell bronchogenic carcinoma. Clinical parameters and survival.

Maddox AM, Valdivieso M, Lukeman J, Smith TL, Barkley HE, Samuels ML, Bodey GP.

Cancer. 1983 Dec 1;52(11):2165-72.

PMID:
6313182

Supplemental Content

Loading ...
Support Center